FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2462387755> ?p ?o ?g. }

• W2462387755 endingPage "46627" @default.
• W2462387755 startingPage "46615" @default.
• W2462387755 abstract "// Vincent Picco 1 , Isabelle Coste 2 , Marie-Josèphe Giraud-Panis 3 , Toufic Renno 2 , Eric Gilson 3, 4 , Gilles Pagès 3 1 Centre Scientifique de Monaco, Biomedical Department, MC-98000 Monaco, Principality of Monaco 2 Centre de Recherche en Cancérologie de Lyon (CRCL), INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008 Lyon, France 3 University of Nice, Sophia Antipolis, Institute for Research on Cancer and Aging, Nice (IRCAN), CNRS UMR7284/INSERM U1081, Medical School, 06107 Nice, France 4 Department of Medical Genetics, Archet 2 Hospital, CHU of Nice, 06200 Nice, France Correspondence to: Gilles Pagès, email: gpages@unice.fr Keywords: cancer, telomere, MAP kinases, phosphorylation, DNA damage Received: March 01, 2016     Accepted: May 23, 2016     Published: June 29, 2016 ABSTRACT Telomere stability is a hallmark of immortalized cells, including cancer cells. While the telomere length is maintained in most cases by the telomerase, the activity of a protein complex called Shelterin is required to protect telomeres against unsuitable activation of the DNA damage response pathway. Within this complex, telomeric repeat binding factor 2 (TRF2) plays an essential role by blocking the ataxia telangiectasia-mutated protein (ATM) signaling pathway at telomeres and preventing chromosome end fusion. We showed that TRF2 was phosphorylated in vitro and in vivo on serine 323 by extracellular signal-regulated kinase (ERK1/2) in both normal and cancer cells. Moreover, TRF2 and activated ERK1/2 unexpectedly interacted in the cytoplasm of tumor cells and human tumor tissues. The expression of non-phosphorylatable forms of TRF2 in melanoma cells induced the DNA damage response, leading to growth arrest and tumor reversion. These findings revealed that the telomere stability is under direct control of one of the major pro-oncogenic signaling pathways (RAS/RAF/MEK/ERK) via TRF2 phosphorylation." @default.
• W2462387755 created "2016-07-22" @default.
• W2462387755 creator A5008550296 @default.
• W2462387755 creator A5013064469 @default.
• W2462387755 creator A5050054883 @default.
• W2462387755 creator A5050665658 @default.
• W2462387755 creator A5083085617 @default.
• W2462387755 creator A5083384975 @default.
• W2462387755 date "2016-06-29" @default.
• W2462387755 modified "2023-10-18" @default.
• W2462387755 title "ERK1/2/MAPK pathway-dependent regulation of the telomeric factor TRF2" @default.
• W2462387755 cites W1518349208 @default.
• W2462387755 cites W1545398558 @default.
• W2462387755 cites W1913244564 @default.
• W2462387755 cites W1969889044 @default.
• W2462387755 cites W1973483964 @default.
• W2462387755 cites W1974732946 @default.
• W2462387755 cites W1982555128 @default.
• W2462387755 cites W1987384318 @default.
• W2462387755 cites W1993745063 @default.
• W2462387755 cites W1994277807 @default.
• W2462387755 cites W1996800742 @default.
• W2462387755 cites W1999334180 @default.
• W2462387755 cites W2002255627 @default.
• W2462387755 cites W2005083925 @default.
• W2462387755 cites W2006498791 @default.
• W2462387755 cites W2007958260 @default.
• W2462387755 cites W2027960166 @default.
• W2462387755 cites W2029580509 @default.
• W2462387755 cites W2033731825 @default.
• W2462387755 cites W2046816202 @default.
• W2462387755 cites W2047832668 @default.
• W2462387755 cites W2049151391 @default.
• W2462387755 cites W2064129448 @default.
• W2462387755 cites W2072367029 @default.
• W2462387755 cites W2073842482 @default.
• W2462387755 cites W2074267794 @default.
• W2462387755 cites W2075938486 @default.
• W2462387755 cites W2076090175 @default.
• W2462387755 cites W2083117403 @default.
• W2462387755 cites W2084960769 @default.
• W2462387755 cites W2087011288 @default.
• W2462387755 cites W2109125373 @default.
• W2462387755 cites W2121438864 @default.
• W2462387755 cites W2127039201 @default.
• W2462387755 cites W2128519375 @default.
• W2462387755 cites W2132144858 @default.
• W2462387755 cites W2143181682 @default.
• W2462387755 cites W2145357417 @default.
• W2462387755 cites W2149058300 @default.
• W2462387755 cites W2152049369 @default.
• W2462387755 cites W2155499815 @default.
• W2462387755 cites W2160185049 @default.
• W2462387755 cites W2160239844 @default.
• W2462387755 cites W2161948433 @default.
• W2462387755 cites W2162471619 @default.
• W2462387755 doi "https://doi.org/10.18632/oncotarget.10316" @default.
• W2462387755 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5216822" @default.
• W2462387755 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27366950" @default.
• W2462387755 hasPublicationYear "2016" @default.
• W2462387755 type Work @default.
• W2462387755 sameAs 2462387755 @default.
• W2462387755 citedByCount "22" @default.
• W2462387755 countsByYear W24623877552017 @default.
• W2462387755 countsByYear W24623877552018 @default.
• W2462387755 countsByYear W24623877552019 @default.
• W2462387755 countsByYear W24623877552020 @default.
• W2462387755 countsByYear W24623877552021 @default.
• W2462387755 countsByYear W24623877552022 @default.
• W2462387755 crossrefType "journal-article" @default.
• W2462387755 hasAuthorship W2462387755A5008550296 @default.
• W2462387755 hasAuthorship W2462387755A5013064469 @default.
• W2462387755 hasAuthorship W2462387755A5050054883 @default.
• W2462387755 hasAuthorship W2462387755A5050665658 @default.
• W2462387755 hasAuthorship W2462387755A5083085617 @default.
• W2462387755 hasAuthorship W2462387755A5083384975 @default.
• W2462387755 hasBestOaLocation W24623877551 @default.
• W2462387755 hasConcept C104317684 @default.
• W2462387755 hasConcept C153911025 @default.
• W2462387755 hasConcept C177336024 @default.
• W2462387755 hasConcept C184235292 @default.
• W2462387755 hasConcept C502942594 @default.
• W2462387755 hasConcept C54355233 @default.
• W2462387755 hasConcept C552990157 @default.
• W2462387755 hasConcept C57074206 @default.
• W2462387755 hasConcept C71924100 @default.
• W2462387755 hasConcept C86803240 @default.
• W2462387755 hasConcept C94581717 @default.
• W2462387755 hasConceptScore W2462387755C104317684 @default.
• W2462387755 hasConceptScore W2462387755C153911025 @default.
• W2462387755 hasConceptScore W2462387755C177336024 @default.
• W2462387755 hasConceptScore W2462387755C184235292 @default.
• W2462387755 hasConceptScore W2462387755C502942594 @default.
• W2462387755 hasConceptScore W2462387755C54355233 @default.
• W2462387755 hasConceptScore W2462387755C552990157 @default.
• W2462387755 hasConceptScore W2462387755C57074206 @default.
• W2462387755 hasConceptScore W2462387755C71924100 @default.
• W2462387755 hasConceptScore W2462387755C86803240 @default.

• next